What are preferred regimens for treatment of multiple myeloma (MM) relapse?

Updated: Mar 06, 2020
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Patients who have a relapse after initial disease control may be treated with any of the agents not already utilized. If the relapse occurs longer than 6 months after the initial therapy, then the initial regimen can be used again.

Among the other choices for salvage therapy are the following preferred regimens [2] :

  • Bortezomib
  • Bortezomib/liposomal doxorubicin
  • Carfilzomib
  • Carfilzomib/dexamethasone
  • Carfilzomib/lenalidomide/dexamethasone
  • Lenalidomide/dexamethasone
  • Panobinostat/bortezomib/dexamethasone
  • Daratumumab
  • Daratumumab/pomalidomide/dexamethasone
  • Daratumumab/lenalidomide/dexamethasone
  • Ixazomib/lenalidomide/dexamethasone
  • Elotuzumab/lenalidomide/dexamethasone
  • Elotuzumab/pomalidomide/dexamethasone
  • Isatuximab/pomalidomide/dexamethasone

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!